DxS seizes molecular diagnostics opportunity with K-RAS test
This article was originally published in Clinica
Executive Summary
UK molecular diagnostics specialist DxS is a company with high expectations. On the strength of its companion diagnostics and research kits for detecting mutations in oncogenes linked to cancer drug response, the Manchester-based company believes it can, in time, dominate the personalised medicine market.